The global cannabis boom is just getting started.
In fact, according to Prohibition Partners, global sales of CBD, medical, and recreational cannabis sales topped $37.4 billion in 2021, and could be on course to see $102 billion in sales by 2026.
“Adult-use markets in the US and Canada remain the most important regions in the world for cannabis sales, but international markets including Germany, Israel and Australia will develop considerably over the next five years,” they noted. “As of late 2021 only Uruguay, Canada and a handful of states in the US have fully legalized cannabis for adult-use, but these will be joined by several international markets soon. Mexico and Israel are primed for full legalization of adult-use cannabis in 2022, while the Netherlands and Switzerland are preparing for their legal pilot trials.”
Even better, analysts at Vantage Market Research say the global market could run to $128.92 billion by 2028, which could be substantially beneficial for Xebra Brands (CSE:XBRA)(OTC:XBRAF), Aurora Cannabis (NASDAQ:ACB)(TSX:ACB), Canopy Growth (TSX:WEED) (NASDAQ:CGC), Tilray Inc. (NASDAQ:TLRY)(TSX:TLRY), and Aleafia Health Inc. (TSX:AH)(OTC:ALEAF).